SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 42854291.
  • 2
    Fossella F, Pereira JR, von Pawel J, et al. Randomized, multicenter, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group. J Clin Oncol. 2003; 21: 30163024.
  • 3
    Kelly K, Crowley J, Bunn PA Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 9: 32103218.
  • 4
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 5
    Taylor EC. Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents. Adv Exp Med Biol. 1993; 338: 387408.
  • 6
    Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57: 11161123.
  • 7
    Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, using the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999; 44: 372380.
  • 8
    Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999; 17: 30093016.
  • 9
    Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999; 17: 11941199.
  • 10
    Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, registered trademark, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol. 2002; 13: 737741.
  • 11
    Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001; 92: 595600.
  • 12
    Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 2000; 11: 435440.
  • 13
    US Food and Drug Administration. FDA News (Online, February 5, 2004).
  • 14
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 26362644.
  • 15
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed compared with docetaxel in non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 15891597.
  • 16
    Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol. 1989; 7: 10871092.
  • 17
    Zatloukal P, Novakova L, Petruzelka L, et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech lung cancer cooperative group phase III randomized trial. Proc Am Soc Clin Oncol. 2002; 21: 307a.
  • 18
    Jelic S, Mitrovic L, Radosavljevic D, et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer. 2001; 34: 113.
  • 19
    Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13: 15391549.
  • 20
    Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 2002; 20: 35333544.
  • 21
    Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmelonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002; 1: 545552.
  • 22
    Bunn PA, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol. 2001; 20: 76a.
  • 23
    Shargel L, Yu ABC. Applied biopharmaceutics, 2nd ed. Norwalk, CT: Appleton-Century-Crofts, 1985. p 310312.
  • 24
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 25
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 26
    Scalgiotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005; 11(2 Pt 1): 690696.
  • 27
    Masotti A, Zannini G, Gentile A, Morandini G. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2002; 36: 99103.
  • 28
    Belani CP, Einzig A, Bonomi P, et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000; 11: 673678.
  • 29
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13: 18601870.
  • 30
    Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997; 15: 297303.
  • 31
    Trousseau A. Phlegmasia alba dolens. Clin Med Hotel dieu de Paris. 1865; 3: 94.
  • 32
    Coon WW. Risk factors in pulmonary embolism. Surg Gynecol Obstet. 1976; 143: 385390.
  • 33
    Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17: 11411145
  • 34
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330353.
  • 35
    Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19: 13361343.
  • 36
    Socinski MA, Kies M, Schell MJ, et al. Duration of therapy in stage IIIB/IV non-small cell lung cancer (NSCLC): a multi-institutional phase III trial. Proc Am Soc Clin Oncol. 2001; 20: 1232a.